2026-10-25
American Healthcare REIT clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,906 −5.38%
S&P 7,400 −3.75%
GOLD $4,127 +1.33%
BTC $76,159 −5.28%
VIX 24.13 +45.27%
latest tape · as of 20:03 UTC
The Screen · Real Estate · REIT - Healthcare Facilities
American Healthcare REIT Inc
AHR · the NYSE · USD · Market cap $11.6B · 121 employees
American Healthcare REIT, Inc., a Maryland-based self-managed REIT, owns and operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man.
Not yet scored56.37 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price56.37 USD at the 4 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 4 Nov 2026
- Our regime readMarkup, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.06)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $39.17 to $45.05, base estimate $39.17 (screen dated 2026-11-04).
- Trend Markup
- Insiders insiders sold, $78,090, latest filing 2026-09-25
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.06, read 2026-11-05
- Ethical screen not yet scored
Price56.37 USD
Fair value39.17
Ethical score70.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-26Read Markup53.40+5.6% to today ✓Markdown gives way to Markup
2026-09-21Read Markdown53.15+6.1% to today Distribution gives way to Markdown after a 14% rise in 12 weeks
2026-07-02Read Distribution46.81+20.4% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
American Healthcare REIT Inc holds its Markup at $56.37. Consolidating, no directional conviction, held for 2 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $56.37 |
| Valuation | 79.70 trailing · 53.94 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.80 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.07% | Below 33% | Interest-bearing debt is just 31.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 5.88% | Below 49% | Money owed to the company is 5.9% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
American Healthcare REIT clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
American Healthcare REIT clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $39.17 fair value estimate, weak competitive moat, 24.70% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 43.9% above the base estimate.
Third-party analyst targets: 16 covering, consensus Strong Buy. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $39.17, with a range of $39.17 to $45.05, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 53.9x forward earnings, the price already runs ahead of the business. It trades 44% above our $39.17 fair value, so you would be buying at a premium, not a discount. The weak moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 53.9xexpensive even after accounting for its growth |
| Trailing P/E | 79.7xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.67 |
| EPS, forward | 0.99 |
| Revenue growth | +24.7%strong top-line growth |
| Profit margin | 4.8%barely profitable |
| Return on equity | 4.0%a modest return on shareholder capital |
| FCF yield | 3.41% |
| Dividend yield | 214.00% |
| Debt to equity | 0.42minimal debt: a conservative balance sheet |
| Current ratio | 1.31adequate liquidity, worth monitoring |
| Beta | 0.80steadier than the market |
| Short interest, float | 0.17% |
| 52-week range | 42.80 - 58.70 |
| Moat | WEAK |
| Market cap | $11.6B |
| Employees | 121 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAHR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Markup $56.37
+2.6% Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Markup $54.93
+2.6% Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markup $53.52
+0.0% Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markup $53.52
+0.0% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markup $53.52
+4.8% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Markup $51.06
+0.0% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Markup $51.06
+0.0% Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Markup $51.06
-4.4% Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Markup · changed $53.40
+0.7% Entry 11
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter.
2026-10-19
Markdown $53.01
+4.4% Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (13 analysts) rates it buy, with a mean price target of $59. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- CubeSmart (CUBE) Surpasses Q3 FFO and Revenue Estimates Yahoo Finance · 7d ago
- SBA Communications to Report Q3 Earnings: What to Expect From SBAC? Yahoo Finance · 7d ago
- What's in the Offing for Ventas Stock This Earnings Season? Yahoo Finance · 13d ago
- SPGI Gears Up to Report Q3 Earnings: Here's What Investors Should Know Yahoo Finance · 13d ago
- Kilroy Realty (KRC) Q3 FFO Lag Estimates Yahoo Finance · 14d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
DOCHealthpeak Properties
OHIOmega Healthcare Investors Inc
CTRECareTrust REIT Inc
HRHealthcare Realty Trust Incorporated
SBRASabra Health Care REIT, Inc.
NHINational Health Investors, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Foster Mark E. | EVP, GC, Secretary | S - Sale | 1,500 | $78,090 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $50.38 | -7.4% | · | $926 | -7.4% |
| 2 months | $49.23 | -5.2% | · | $948 | -5.2% |
| 3 months | $51.85 | -10.0% | $0.25 | $905 | -9.5% |
| 6 months | $46.21 | +1.0% | $0.50 | $1,021 | +2.1% |
| 1 year | $34.43 | +35.5% | $1.00 | $1,384 | +38.4% |
| 2 years | $13.87 | +236.4% | $2.00 | $3,508 | +250.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AHR does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.